23:56 , Jul 26, 2018 |  BC Extra  |  Company News

Reese succeeding Harper as Amgen EVP of R&D

Amgen Inc. (NASDAQ:AMGN) said EVP of R&D Sean Harper will retire and be succeeded by SVP of Translational Sciences and Oncology David Reese. The company also reported 2Q18 earnings on Thursday after market hours that...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
23:21 , Nov 30, 2017 |  BC Week In Review  |  Company News

Amgen buys out Kyowa JV

In October, Amgen Inc. (NASDAQ:AMGN) and Kirin Holdings Co. Ltd. terminated their JV Kirin-Amgen, which now becomes a wholly-owned subsidiary of Amgen. Kirin is the parent company of Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151). Kirin...
21:06 , Jan 27, 2017 |  BC Week In Review  |  Company News

Amgen, DaVita deal

Amgen will supply DaVita with anemia drugs Epogen epoetin alfa and Aranesp darbepoetin alfa for use in DaVita’s dialysis services in the U.S. and Puerto Rico. Amgen will provide at least 90% of DaVita’s required...
00:53 , Dec 31, 2016 |  BioCentury  |  Finance

Delivering takeouts

  BioCentury’s 25th annual Buyside View finds biotech investors focusing on mid-cap names with late-stage or marketed products that could become M&A targets. “The main theme playing at the moment is investors like us are...
11:42 , Dec 1, 2016 |  BC Week In Review  |  Clinical News

Daprodustat: Ph III started

GlaxoSmithKline began the open-label, U.S. Phase III ASCEND-ND trial to compare oral daprodustat once daily vs. subcutaneous darbepoetin alfa in about 4,500 non-dialysis-dependent patients switching from, or are naïve to, an erythropoietin-stimulating agent (ESA). Patients...
11:42 , Dec 1, 2016 |  BC Week In Review  |  Clinical News

Daprodustat: Ph III started

GlaxoSmithKline began the open-label, U.S. Phase III ASCEND-D trial to compare oral daprodustat once daily vs. subcutaneous or IV darbepoetin alfa in about 3,000 dialysis patients switching from an erythropoietin-stimulating agent (ESA). Patients will have...
07:00 , Sep 12, 2016 |  BioCentury  |  Politics, Policy & Law

Executive power

Years of congressional gridlock have caused power in Washington to shift to the White House, making the levers of power less accessible to pharmaceutical industry lobbyists. While Congress will continue to mine outrage over drug...
07:00 , Aug 22, 2016 |  BC Week In Review  |  Clinical News

Vadadustat: Phase III started

Akebia began the open-label, international Phase III INNO2VATE-Correction trial to compare oral vadadustat vs. subcutaneous or IV Aranesp darbepoetin alfa in about 400 treatment-naive, dialysis-dependent patients. The trial is part of the international Phase III...
08:00 , Feb 22, 2016 |  BC Week In Review  |  Clinical News

Darbepoetin alfa: Phase III data

The double-blind, international Phase III ARCADE trial in 146 anemic patients with low or intermidate-1 risk MDS who had not previously taken erythropoiesis-stimulating agents (ESAs) or biologic response modifiers showed that 500 ug Aranesp every...